H-P’s Cost Cutting, Valuation Could Mean a 20% Rise in Shares Over the Next Year, Says Barron’s April 14, 2014 on BioPharma, Consumer Cyclicals, Diversified Financial, Macro Markets, Software & Services by James Lavish Barron says that, H-P’s valuation could mean a 20% rise in the next 12 months.
